243 related articles for article (PubMed ID: 37316442)
41. Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions.
Oxnard GR; Lo PC; Nishino M; Dahlberg SE; Lindeman NI; Butaney M; Jackman DM; Johnson BE; Jänne PA
J Thorac Oncol; 2013 Feb; 8(2):179-84. PubMed ID: 23328547
[TBL] [Abstract][Full Text] [Related]
42. EGFR exon 20 Insertion NSCLC and Response to Platinum-Based Chemotherapy.
Shah MP; Aredo JV; Padda SK; Ramchandran KJ; Wakelee HA; Das MS; Neal JW
Clin Lung Cancer; 2022 Mar; 23(2):e148-e153. PubMed ID: 34391686
[TBL] [Abstract][Full Text] [Related]
43. Uncommon EGFR mutations in non-small-cell lung cancer: A systematic literature review of prevalence and clinical outcomes.
John T; Taylor A; Wang H; Eichinger C; Freeman C; Ahn MJ
Cancer Epidemiol; 2022 Feb; 76():102080. PubMed ID: 34922050
[TBL] [Abstract][Full Text] [Related]
44. Non-small cell lung cancer with
Kwon CS; Lin HM; Crossland V; Churchill EN; Curran E; Forsythe A; Tomaras D; Ou SI
Curr Med Res Opin; 2022 Aug; 38(8):1341-1350. PubMed ID: 35621011
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of Epidermal Growth Factor Receptor Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer in Europe: A Pragmatic Literature Review and Meta-analysis.
Van Sanden S; Murton M; Bobrowska A; Rahhali N; Sermon J; Rodrigues B; Goff-Leggett D; Chouaid C; Sebastian M; Greystoke A
Target Oncol; 2022 Mar; 17(2):153-166. PubMed ID: 35226283
[TBL] [Abstract][Full Text] [Related]
46. The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations.
Hernandez L; Young M
J Manag Care Spec Pharm; 2023 Feb; 29(2):172-186. PubMed ID: 36373869
[No Abstract] [Full Text] [Related]
47. Therapeutic exploration of uncommon EGFR exon 20 insertion mutations in advanced non-small cell lung cancer: breaking through brambles and thorns.
Bai R; Chen X; Song W; Tian H; Cui J
J Cancer Res Clin Oncol; 2022 Jan; 148(1):163-176. PubMed ID: 34698913
[TBL] [Abstract][Full Text] [Related]
48. Epidemiological and clinical burden of EGFR Exon 20 insertion in advanced non-small cell lung cancer: A systematic literature review.
Burnett H; Emich H; Carroll C; Stapleton N; Mahadevia P; Li T
PLoS One; 2021; 16(3):e0247620. PubMed ID: 33684140
[TBL] [Abstract][Full Text] [Related]
49. Indirect comparison of mobocertinib and real-world therapies for pre-treated non-small cell lung cancer with EGFR exon 20 insertion mutations.
Christopoulos P; Prawitz T; Hong JL; Lin HM; Hernandez L; Jin S; Tan M; Proskorovsky I; Lin J; Zhang P; Patel JD; Ou SI; Thomas M; Stenzinger A
Lung Cancer; 2023 May; 179():107191. PubMed ID: 37058788
[TBL] [Abstract][Full Text] [Related]
50. [The research status and development trend of EGFR gene exon 20 insertion mutant non-small cell lung cancer].
Yang GJ; Wang Y
Zhonghua Zhong Liu Za Zhi; 2020 Jan; 42(1):22-29. PubMed ID: 32023765
[TBL] [Abstract][Full Text] [Related]
51. Identification of non-small-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry.
Kawahara A; Azuma K; Sumi A; Taira T; Nakashima K; Aikawa E; Abe H; Yamaguchi T; Takamori S; Akiba J; Kage M
Lung Cancer; 2011 Oct; 74(1):35-40. PubMed ID: 21444121
[TBL] [Abstract][Full Text] [Related]
52. Pembrolizumab and chemotherapy in non-small cell lung cancer with EGFR ex20ins mutation: A case report.
Zhang M; Nie L; Cheng Y
Thorac Cancer; 2021 Oct; 12(20):2803-2806. PubMed ID: 34382340
[TBL] [Abstract][Full Text] [Related]
53. EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer.
Fang W; Huang Y; Hong S; Zhang Z; Wang M; Gan J; Wang W; Guo H; Wang K; Zhang L
BMC Cancer; 2019 Jun; 19(1):595. PubMed ID: 31208370
[TBL] [Abstract][Full Text] [Related]
54. [Correlation Study on Expression of PD-1 and PD-L1 in Non-small Cell Lung Cancer and Epidermal Growth Factor Receptor Mutations].
Jiang L; Lin Z; Li N; Jiang J; Lu C; Du S; Zhang J; Wang Y; Chen J; Gong P
Zhongguo Fei Ai Za Zhi; 2021 Sep; 24(9):623-631. PubMed ID: 34455737
[TBL] [Abstract][Full Text] [Related]
55. Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer.
Yasuda H; Park E; Yun CH; Sng NJ; Lucena-Araujo AR; Yeo WL; Huberman MS; Cohen DW; Nakayama S; Ishioka K; Yamaguchi N; Hanna M; Oxnard GR; Lathan CS; Moran T; Sequist LV; Chaft JE; Riely GJ; Arcila ME; Soo RA; Meyerson M; Eck MJ; Kobayashi SS; Costa DB
Sci Transl Med; 2013 Dec; 5(216):216ra177. PubMed ID: 24353160
[TBL] [Abstract][Full Text] [Related]
56. Positive progress for non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: A novel targeted therapy option.
Zhang W; Dong X
J Oncol Pharm Pract; 2021 Dec; 27(8):2007-2009. PubMed ID: 34569378
[TBL] [Abstract][Full Text] [Related]
57. Real-World Patient Characteristics, Treatment Patterns, and Mutation Testing Patterns Among US Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
He J; Pericone CD; Vanderpoel J
Adv Ther; 2022 Jul; 39(7):3347-3360. PubMed ID: 35674970
[TBL] [Abstract][Full Text] [Related]
58. Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor.
Jang J; Son J; Park E; Kosaka T; Saxon JA; De Clercq DJH; Choi HG; Tanizaki J; Eck MJ; Jänne PA; Gray NS
Angew Chem Int Ed Engl; 2018 Sep; 57(36):11629-11633. PubMed ID: 29978938
[TBL] [Abstract][Full Text] [Related]
59. Real-world clinical treatment outcomes in Chinese non-small cell lung cancer with
Shi C; Xing R; Li M; Feng J; Sun R; Wei B; Guo Y; Ma J; Wang H
Front Oncol; 2022; 12():949304. PubMed ID: 36119499
[TBL] [Abstract][Full Text] [Related]
60. The Frequency of Epidermal Growth Factor Receptor (EGFR) mutations in Iraqi patients with Non-Small Cell Lung Cancer (NSCLC).
Ramadhan HH; Taaban DF; Hassan JK
Asian Pac J Cancer Prev; 2021 Feb; 22(2):591-596. PubMed ID: 33639678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
